Protalix BioTherapeutics Appoints David Granot to its Board of Directors
August 13 2018 - 7:00AM
Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX),
announced today that the Company’s Board of Directors has appointed
Mr. David Granot to serve on the Company’s Board of Directors,
effective on August 9, 2018. In addition to Mr. Granot’s
appointment as an independent director, he was also appointed to
serve on the Company’s Audit Committee.
“We are very pleased to have David join our Board of Directors,”
commented Shlomo Yanai, Chairman of Protalix’s Board of
Directors. “He brings extensive financial and banking
knowledge, as well as vast management and business experience,
which will be a valuable contribution to the Board as Protalix
continues to execute its strategic plan.”
Mr. Granot currently serves on the Board of Directors of Ormat
Technologies, Inc. (NYSE:ORA). He also serves on the board of
directors of Bezeq Israeli Telecommunication, Co. Ltd. (BEZQ:TASE)
since May 22, 2012, where he served as temporary Acting Chairman,
July 2017 through May 2018; Alrov Properties & Lodgings Ltd.
(ALRPR:TASE); and Jerusalem Economy Ltd. (ECJM:TASE), each of which
are Israeli public companies. He also serves on the board of
directors of other privately-held companies. Until March
2013, he was a director of Harel Insurance Investments and
Financial Ltd. and Chairman of the Nostro investment committee of
Harel Insurance. From 2001 through 2007, he served as the
Chief Executive Officer of the First International Bank of Israel
Ltd, from 1998 through 2000 he served as the Chief Executive
Officer of the Israel Discount Bank and from 1995 through 1998, he
served as the Chief Executive Officer of the Israel Union
Bank. Mr. Grant holds a B.A. in Economics and an MBA, both
from the Hebrew University of Jerusalem.
About Protalix BioTherapeutics,
Inc.
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell-based
expression system, ProCellEx®. Protalix’s unique expression
system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.
Protalix’s first product manufactured by ProCellEx, taliglucerase
alfa, was approved for marketing by the U.S. Food and Drug
Administration (FDA) in May 2012 and, subsequently, by the
regulatory authorities of other countries. Protalix has
licensed to Pfizer Inc. the worldwide development and
commercialization rights for taliglucerase alfa, excluding Brazil,
where Protalix retains full rights. Protalix’s development
pipeline includes the following product candidates: pegunigalsidase
alfa, a modified version of the recombinant human alpha-GAL-A
protein for the treatment of Fabry disease; OPRX-106, an
orally-delivered anti-inflammatory treatment; alidornase alfa for
the treatment of Cystic Fibrosis; and others. Protalix
partnered with Chiesi Farmaceutici S.p.A., both in the United
States and outside the United States, for the development and
commercialization of pegunigalsidase alfa.
Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and
are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. The terms “expect,”
“anticipate,” “believe,” “estimate,” “project,” “plan,” “should”
and “intend” and other words or phrases of similar import are
intended to identify forward-looking statements. These
forward-looking statements are subject to known and unknown risks
and uncertainties that may cause actual future experience and
results to differ materially from the statements made. These
statements are based on our current beliefs and expectations as to
such future outcomes. Drug discovery and development involve
a high degree of risk, and various factors may cause differences
between our expectations and actual results as discussed in greater
detail in our filings with the Securities and Exchange
Commission. The statements in this press release are valid
only as of the date hereof and we disclaim any obligation to update
this information, except as may be required by law.
Investor Contact
Marcy Nanus Solebury Trout 646-378-2927
mnanus@soleburytrout.com
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2023 to Apr 2024